Skip to Main Content

Rafael Pharmaceuticals said Thursday that its experimental treatment for pancreatic cancer failed to prolong the lives of patients in a large clinical trial.

A separate study of the same Rafael drug, called devimistat, involving patients with a type of leukemia, was also stopped early after an interim analysis concluded the drug was not working, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment